The role and data driven basis for radioembolization remains ill-defined with recent phase III randomized trials negative for patients with hepatocellular carcinoma (HCC), and only a single second line trial in metastatic colorectal cancer (CRC) meeting its primary endpoint progression-free survival (EPOCH, NCT01483027) . Few studies are currently underway to define and/or clarify the role of radioembolization. The search term “radioembolization OR SIRT OR TheraSphere OR TARE” (status: Aug. 2022), revealed 44 clinical trials at clinicaltrials.gov, of which only 25 are currently recruiting. However, additional active trials can be found in registries such as the European Union´s register EudraCT (2 additional active trials)  or national such as the German DRKS (3 additional active trials) . Stratifying ongoing clinical trials as published in PubMed or clinicaltrials.gov, the following categories can be defined: (a) clinical trials evaluating the efficacy of SIRT in different tumor biologies metastatic to or primaries of the liver; as the most important subgroup, evaluation of combination therapies with systemic treatment, predominantly combining with checkpoint inhibition, including basic research seeking immune-modulating mechanisms and proof in tissue or blood; (b) assessing new technologies such as Holmium-166 for SIRT; and (c) new approaches (e.g., highly selected patient group) and indications for SIRT, also outside the liver.
The only phase III trial ongoing likely is STOP-HCC (NCT01556490), with advanced HCC patients receiving sorafenib ± radioembolization. Primary endpoint is overall survival, results are expected for end of 2022. However, this concept may come late given most recent developments in systemic HCC treatment shifting to immune checkpoint inhibition [4, 5]. Considering the presumptive immunomodulatory effect of radioembolization such combination therapies might be the future domain of radioembolization, which is supported by the results of a recently published phase II study from Singapore (NCT03033446, radioembolization + Nivolumab)  as well as by the promising preliminary results of a phase I (NCT03099564, radioembolization + Pembrolizumab)  and phase II study (NCT03380130, radioembolization + Nivolumab) . Therefore, phase II trials such as IMMUWIN (NCT04522544; randomized, radioembolization or transarterial chemoembolization [TACE] combined with Durvalumab/Tremelimumab, primary endpoint objective response rate [ORR], completion 2024), SOLID (NCT04124991; single arm, radioembolization + Durvalumab, time-to-progression, completion 2022) or ROWAN (NCT05063565; randomized, radioembolization alone vs. radioembolization + Durvalumab/Tremelimumab, ORR, completion 2026) are of utmost interest for positioning radioembolization in HCC future treatment strategies. Recently evolved, the ZUGSPITZE trial, may add mechanistic as well as conceptual data through an extensive basic research program (EudraCT 2020-003,925-42, Sponsor LMU München, randomized three arm study, radioembolization standard vs. personalized dose + Durvalumab/Tremelimumab vs.checkpoint first followed by radioembolization on demand, endpoint ORR, completion estimated 2025). Further Phase II single arm studies combining radioembolization and immune checkpoint inhibition target cholangiocellular carcinoma (IMMUWHY, NCT04238637), CRC (SIRTCI, NCT04659382; iRE-C, NCT04108481) or neuroendocrine tumors (NCT03457948). Finally, the only active clinical cancer trial for non-liver indications seems to be POEM (DRKS00021723), a phase I/II trial assessing safety and efficacy as a composite endpoint when using the bronchial arteries to target primary or secondary lung malignancies. Completion is expected 2023. Table 1 provides a selected overview of currently ongoing trials with comments regarding the crucial characteristics of each study.
In summary, only a small number of clinical trials are currently active, almost all limited to small Phase II concepts. Given the lack of comprehensive data on the clinical benefit of radioembolization, emerging data clearly will not suffice to secure radioembolization as integral part of future treatment strategies and guidelines.
Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG, 2nd; Herrmann K, Brown E, Zuckerman D, Wilson G et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol: Official J Am Soc Clin Oncol 2021, Jco2101839, https://doi.org/10.1200/jco.21.01839.
EudraCT. EU Clinical Trials Register. Available online: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004512-19/FR (accessed on 2022, August 14).
German Clinical Trials Register. Deutschen register klinischer studien (DRKS). Available online: https://www.drks.de/drks_web/ (accessed on 2022, August 14).
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.
Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2022; https://doi.org/10.1016/j.jhep.2021.11.018.
Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209–678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:1025–35. https://doi.org/10.1016/s2468-1253(21)00305-8.
McRee AJ, Helft PR, Harris WP, Sanoff HK, Johnson M, Yu M, O’Neil B. A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC) with preserved liver function. J Clin Oncol. 2022;40:422–422. https://doi.org/10.1200/JCO.2022.40.4_suppl.422.
Sangro, B. Nivolumab after selective internal radiation therapy (SIRT) using SIR-spheres resin microspheres in patients with hepatocellular carcinoma: the NASIR-HCC trial. In Proceedings of the Proceedings of the 14th Annual Conference of the International Liver Cancer Association (ILCA), Madrid, Spain, 2020; pp. 11–13.
Open Access funding enabled and organized by Projekt DEAL. This study was not supported by any funding.
Conflict of interest
Jens Ricke declares consulting, advisory arrangements, and research grants and travel grants from Sirtex Medical, and consulting, advisory arrangements and receiving travel grants from BTG. Matthias P. Fabritius has no conflicts of interest to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fabritius, M.P., Ricke, J. Overview of Ongoing Clinical Trials on Radioembolization. Cardiovasc Intervent Radiol 45, 1659–1662 (2022). https://doi.org/10.1007/s00270-022-03270-4